Avalo Therapeutics Inc AVTX

Healthcare Biotechnology

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß) with high affinity and neutralizes its activity. IL- 1ß is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

NDAQ:AVTX - Post by User

Avalo Therapeutics Inc > AVTX....crucial pivot right here at over $5

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Mar 06, 2024 3:41pm

54 Views

Post# 35918870

RE:AVTX....crucial pivot right here at over $5

Iseneschal wrote: Coin toss time.....this has got to pop with volume or it will retrace back to the lower part of the "sideways channel"

Just my 2 bits....last at $5.12

20 minutes left til closing........All I can say is ....if .... this can bust thru $5.30 with volume and a NR....you won't have time to buy it

In other words don't blink ....you just might miss the move ; )

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages